Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3524-3530

  Kostense, Stefan ^a   Moore, Susan ^b   Companjen, Arjen ^a   Bakker, Alexander B H ^a,c   Marissen, Wilfred E ^a   Von Eyben, Rie ^a   Weverling, Gerrit Jan ^a   Hanlon, Cathleen ^b   Goudsmit, Jaap ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b KANSAS STATE UNIVERSITY   (United States)

^c Merus BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; NONHUMAN; PRIORITY JOURNAL; RABIES VIRUS; RAPID FLUORESCENT FOCUS INHIBITION TEST; VALIDATION PROCESS; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; HUMANS; IMMUNOGLOBULINS; NEUTRALIZATION TESTS; RABIES VACCINES; RABIES VIRUS;

EID: 84862583126     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06179-11     Document Type: Article

References (18)

1. Bakker AB, et al. 2005. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 79:9062-9068.
2. Bakker AB, et al. 2008. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26:5922-5927.
3. Dodet B. 2007. An important date in rabies history. Vaccine 25:8647-8650.
4. FDA. 2001. Guidance for industry. Bioanalytical method validation. Food and Drug Administration, Rockville, MD.
5. Goudsmit J, et al. 2006. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J. Infect. Dis. 193:796-801.
6. Habel K. 1996. Habel test for potency, p 369-373. In Meslin FX, Kaplan MM, Koprowski H (ed), Laboratory techniques in rabies, 4th ed. World Health Organization, Geneva, Switzerland.
7. ICH. 2005. Validation of analytical procedures: text and methodology Q2(R1). ICH, Geneva, Switzerland.
8. Johnson R. 2008. Assessment of bias with emphasis on method comparison. Clin. Biochem. Rev. 29(Suppl 1):S37-S42.
9. Manning SE, et al. 2008. Human rabies prevention - United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. 57:1-28.
10. Marissen WE, et al. 2005. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J. Virol. 79:4672-4678.
11. Moore SM, Hanlon CA. 2010. Rabies-specific antibodies: measuring surrogates of protection against a fatal disease. PLoS Negl. Trop. Dis. 4:e595.
12. Rupprecht CE, Gibbons RV. 2004. Clinical practice. Prophylaxis against rabies. N. Engl. J. Med. 351:2626-2635.
13. Smith JS, Yager PA, Baer GM. 1973. A rapid reproducible test for determining rabies neutralizing antibody. Bull. World Health Organ. 48:535-541.
14. Viswanathan CT, et al. 2007. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24:1962-1973.
15. WHO. 2011. The immunological basis for immunization series, module 17: rabies. World Health Organization, Geneva, Switzerland.
16. WHO. 2010. Rabies vaccines: WHO position paper-recommendations. Vaccine 28:7140-7142.
17. WHO. 2002. WHO consultation on a rabies monoclonal antibody cocktail for rabies post exposure treatment. World Health Organization, Geneva, Switzerland. http://www.who.int/rabies/vaccines/en/mabs-final-report.pdf.
18. WHO. 1997.WHOrecommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO/EMC/ZOO/96.6. World Health Organization, Geneva, Switzerland. 〈http://whqlibdoc.who.int/ hq/1996/WHO-EMC-ZOO-96.6.pdf〉.